Answers are grounded in this paper and cite their sources.
Autologous CD19/CD20 bispecific CAR-T cell therapy generated from TN/MEM cells for patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and demonstrates strong efficacy (90% ORR, 70% CR rate) in a first-in-human, phase I dose-escalation trial. This article is highlighted in the In This Issue feature, p. 517.
No takes yet. Share an insight, caveat, or question.
Larson et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: